205 related articles for article (PubMed ID: 30689953)
1. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
2. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.
Bestgen B; Kufareva I; Seetoh W; Abell C; Hartmann RW; Abagyan R; Le Borgne M; Filhol O; Cochet C; Lomberget T; Engel M
J Med Chem; 2019 Feb; 62(4):1817-1836. PubMed ID: 30689946
[TBL] [Abstract][Full Text] [Related]
3. Structural and Mechanistic Basis of the Inhibitory Potency of Selected 2-Aminothiazole Compounds on Protein Kinase CK2.
Lindenblatt D; Nickelsen A; Applegate VM; Jose J; Niefind K
J Med Chem; 2020 Jul; 63(14):7766-7772. PubMed ID: 32589844
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
5. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
6. Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.
Brear P; Ball D; Stott K; D'Arcy S; Hyvönen M
J Med Chem; 2020 Nov; 63(21):12786-12798. PubMed ID: 33119282
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies.
Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
9. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
11. A novel allosteric site in casein kinase 2α discovered using combining bioinformatics and biochemistry methods.
Jiang HM; Dong JK; Song K; Wang TD; Huang WK; Zhang JM; Yang XY; Shen Y; Zhang J
Acta Pharmacol Sin; 2017 Dec; 38(12):1691-1698. PubMed ID: 28748912
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
[TBL] [Abstract][Full Text] [Related]
13. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
[TBL] [Abstract][Full Text] [Related]
14. Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.
Tang S; Zhang N; Zhou Y; Cortopassi WA; Jacobson MP; Zhao LJ; Zhong RG
Mol Inform; 2019 Mar; 38(3):e1800089. PubMed ID: 30307134
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of synthetic 4'-hydroxyflavones-New CK2 inhibitors from flavone family.
Golub AG; Bdzhola VG; Ostrynska OV; Kyshenia IV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Yarmoluk SM
Bioorg Med Chem; 2013 Nov; 21(21):6681-9. PubMed ID: 24011954
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for the design of bisubstrate inhibitors of protein kinase CK2 provided by complex structures with the substrate-competitive inhibitor heparin.
Schnitzler A; Niefind K
Eur J Med Chem; 2021 Mar; 214():113223. PubMed ID: 33571828
[TBL] [Abstract][Full Text] [Related]
17. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
18. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
[TBL] [Abstract][Full Text] [Related]
19. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]